NCT03513172View on ClinicalTrials.gov

Pre-Administration of Brimonidine in Intravitreal Anti-VEGF Therapy

NACompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

December 15, 2016

Primary Completion Date

July 15, 2017

Study Completion Date

September 1, 2017

Conditions
Post-Injection Intraocular Pressure Spikes
Interventions
DRUG

topical brimonidine tartrate 0.15% (Alphagan® P; Allergan, Inc)

The rapid hypotensive effects of topical alpha2-agonists such as brimonidine tartrate on decreasing aqueous production and increasing uveoscleral outflow, in addition to their neuroprotective properties, make them an attractive option for prophylactic treatment of post-injection IOP spikes.

All Listed Sponsors
collaborator

Dr. Efrem Mandelcorn

UNKNOWN

lead

University of Toronto

OTHER

NCT03513172 - Pre-Administration of Brimonidine in Intravitreal Anti-VEGF Therapy | Biotech Hunter | Biotech Hunter